Synthetic Biologics Inc. (SYN) saw an uptrend of 30.57% in the recent, registering $0.50 being its most recent bid. The distance of current price level is -33.32% lower than the highest price of $0.75 marked by the stock while trading over the past 52-weeks, whereas it is 98.30% higher than the lowest price of $0.25 the company dropped to over past 52-weeks. The latest news story on SYN appeared in PR Newswire under the title “Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol” on Dec-22-20.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Squeezing the time span to 30 day period shows us the stock currently buoying -10.98% below one month high and is +56.28% above of the lowest during that time. Looking into the simple moving average, Synthetic Biologics Inc. (SYN)’s stock is currently standing at a SMA-50 of $0.3556 while that of 5-day is reading $0.4069.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and SYN’s SMA-200 at this time is reading $0.4182.
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Synthetic Biologics Inc. (SYN) releasing its most recent results for the quarter ended 9/29/2020 posted a surprise factor of 17.60% for net revenue.
Looking into the perspective of Synthetic Biologics Inc. (AMEX:SYN)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.17 for stock’s EPS in the current quarter. 2 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.14.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). Institutions currently hold 19.99 million of SYN’s outstanding shares. That indicates a holding of about 7.10% or $14.0 of worth by institutional holders in the company.
As on Sep 29, 2020, Renaissance Technologies, LLC was the top most holder in Synthetic Biologics Inc. (AMEX:SYN) with an ownership of 0.86 million shares of the company or 4.30% of the stake worth $0.41 million. The filing also reveals Vanguard Group, Inc. (The) as the second largest holder in the company with a control over 0.62% of the stake or worth of $58575.0 for having 0.12 million shares in hand.
Bridgeway Capital Management, Inc. also came increasing its position in the company during the recent quarter and it now holds 0.55% of the outstanding shares. With this there are now 28 institutions which have been in possession of SYN’s shares.
Investors are for sure keenly observing the recommendations of analysts at Wall Street about the Synthetic Biologics Inc. And review of current evaluations agreed by the analysts discloses a Buy rating for SYN. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.50 for the stock. Lower value of between 1 and 2 implies a Buy recommendation whereas the value in the range of above 4 suggests Hold while below 1 recommends the investors to Sell the stock. Currently, the stock has been recommended as Moderate Buy by 1 of the Wall Street analysts.
Company attained a return on equity (ROE) of 207.90% in past 12 months against the same posted by peer companies of the relevant industry. The rising figure indicates that SYN came strengthening itself from within over the past one year. A comparison of company’s ROE with that of the Biotechnology industry and with the broader scale at the Healthcare sector level shows that industry’s average ROE is -46.42.
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term average volume of a stock is an effective way to make use of. When looking into those indicators for Synthetic Biologics Inc. (SYN), we notice that the stock’s 20-day average volume is at 2,711,045 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 1,402,398 shares. And to end with, SYN’s 100-day average volume are 983,345 shares with 50% of the long-term indicators pointing towards Buy for the stock.